Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICS tapering versus continuation in obese T2-low asthma
NL-OMON55120Phase 4Recruiting
- Sponsor
- Franciscus Gasthuis & Vlietland
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fluticasone, fenoterol and ipratropium bromide in asthma, Type 2 low asthma and obesity-associated asthma (3 arms), sponsored by Franciscus Gasthuis & Vlietland. Primary endpoint: Sustained asthma control after ICS tapering. Started Mar 2021; status: recruiting.
02
Drugs
fluticasonefenoterolipratropium bromide
03
Conditions
asthmaType 2 low asthmaobesity-associated asthma
Beyond the preview
Go deeper on NL-OMON55120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55120.